-
EP1267915
European procedure
Extract from the Register of European Patents
EP About this file: EP1267915
| EP1267915 - ACTIVATED PROTEIN C FOR TREATING PANCREATITIS [Right-click to bookmark this link] | |||
| Former [2003/01] | METHODS OF TREATING DISEASES WITH ACTIVATED PROTEIN C | ||
| [2004/43] | Status | No opposition filed within time limit Status updated on 05.05.2006 Database last updated on 12.07.2024 | Most recent event Tooltip | 05.05.2006 | No opposition filed within time limit | published on 07.06.2006 [2006/23] | Applicant(s) | For all designated states ELI LILLY AND COMPANY Lilly Corporate Center Indianapolis, IN 46285 / US | [N/P] |
| Former [2003/01] | For all designated states ELI LILLY AND COMPANY Lilly Corporate Center Indianapolis, Indiana 46285 / US | Inventor(s) | 01 /
CIACCIA, Angelina, Vucic 5204 North Graceland Avenue Indianapolis, IN 46208 / US | 02 /
GELBERT, Lawrence, Mark 5348 Central Avenue Indianapolis, IN 46220 / US | 03 /
GRINNELL, Brian, William 3625 East 71st Street Indianapolis, IN 46220 / US | 04 /
JONES, Bryan, Edward 14772 Beacon Park Drive Carmel, IN 46032 / US | 05 /
JOYCE, David, Eugene 4318 Falcon Drive Bloomington, IN 47403 / US | [2003/01] | Representative(s) | Burnside, Ivan John, et al Eli Lilly and Company Limited 8 Arlington Square West Downshire Way Bracknell, Berkshire RG12 1PU / GB | [N/P] |
| Former [2003/01] | Burnside, Ivan John, et al Eli Lilly and Company Limited European Patent Operations Erl Wood Manor Sunninghill Road Windlesham, Surrey GU20 6PH / GB | Application number, filing date | 01918217.9 | 21.03.2001 | [2003/01] | WO2001US05823 | Priority number, date | US20000192755P | 28.03.2000 Original published format: US 192755 P | [2003/01] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO0172328 | Date: | 04.10.2001 | Language: | EN | [2001/40] | Type: | A2 Application without search report | No.: | EP1267915 | Date: | 02.01.2003 | Language: | EN | The application published by WIPO in one of the EPO official languages on 04.10.2001 takes the place of the publication of the European patent application. | [2003/01] | Type: | B1 Patent specification | No.: | EP1267915 | Date: | 22.06.2005 | Language: | EN | [2005/25] | Search report(s) | International search report - published on: | EP | 14.02.2002 | Classification | IPC: | A61K38/48, C12Q1/68, A61P1/00, A61P3/00, A61P7/00, A61P11/00, A61P13/00, A61P17/00, A61P19/00, A61P25/00, A61P31/00, A61P35/00, // G01N33/50, A61P1/18 | [2004/43] | CPC: |
C12Q1/6883 (EP);
A61K38/4866 (EP);
A61P1/00 (EP);
A61P1/04 (EP);
A61P1/16 (EP);
A61P1/18 (EP);
A61P11/00 (EP);
A61P13/00 (EP);
A61P13/12 (EP);
A61P17/00 (EP);
A61P17/06 (EP);
A61P19/00 (EP);
A61P19/02 (EP);
A61P19/10 (EP);
A61P25/00 (EP);
A61P25/16 (EP);
A61P25/28 (EP);
A61P29/00 (EP);
A61P3/00 (EP);
A61P3/10 (EP);
A61P31/00 (EP);
A61P35/00 (EP);
A61P37/00 (EP);
A61P37/06 (EP);
A61P5/14 (EP);
A61P7/00 (EP);
A61P9/00 (EP);
C12Q2600/158 (EP)
(-)
|
| Former IPC [2003/01] | A61K38/48, C12Q1/68, A61P1/00, A61P3/00, A61P7/00, A61P11/00, A61P13/00, A61P17/00, A61P19/00, A61P25/00, A61P31/00, A61P35/00, // G01N33/50 | Designated contracting states | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR [2003/01] | Extension states | AL | Not yet paid | LT | Not yet paid | LV | Not yet paid | MK | Not yet paid | RO | Not yet paid | SI | Not yet paid | Title | German: | AKTIVIERTES PROTEIN C ZUR BEHANDLUNG VON PANKREATITIS | [2004/43] | English: | ACTIVATED PROTEIN C FOR TREATING PANCREATITIS | [2004/43] | French: | PROTEINE C ACTIVEE POUR LE TRAITEMENT DE LA PANCREATITE | [2004/43] |
| Former [2003/01] | METHODEN ZUR BEHANDLUNG VON KRANKHEITEN MIT AKTIVIERTEM PROTEIN C | ||
| Former [2003/01] | METHODS OF TREATING DISEASES WITH ACTIVATED PROTEIN C | ||
| Former [2003/01] | METHODES DE TRAITEMENT DE MALADIES A L'AIDE DE LA PROTEINE C ACTIVEE | Entry into regional phase | 28.10.2002 | National basic fee paid | 28.10.2002 | Designation fee(s) paid | 28.10.2002 | Examination fee paid | Examination procedure | 01.10.2001 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 28.10.2002 | Examination requested [2003/01] | 24.07.2003 | Despatch of a communication from the examining division (Time limit: M06) | 13.02.2004 | Reply to a communication from the examining division | 14.10.2004 | Communication of intention to grant the patent | 24.02.2005 | Fee for grant paid | 24.02.2005 | Fee for publishing/printing paid | Opposition(s) | 23.03.2006 | No opposition filed within time limit [2006/23] | Request for further processing for: | 13.02.2004 | Request for further processing filed | 13.02.2004 | Full payment received (date of receipt of payment) Request granted | 01.03.2004 | Decision despatched | Fees paid | Renewal fee | 31.03.2003 | Renewal fee patent year 03 | 31.03.2004 | Renewal fee patent year 04 | 31.03.2005 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO9920293 (LILLY CO ELI [US], et al) [X] 1-15 * the whole document *; | [XA] - GREY S T ET AL, "Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-gamma, or phorbol ester.", JOURNAL OF IMMUNOLOGY, (19941015), vol. 153, no. 8, pages 3664 - 3672, XP000567838 [X] 5,14,15 * page 3666, column R * * the whole document * [A] | [A] - ESMON C T ET AL, "Inflammation: The protein C pathway.", FIBRINOLYSIS & PROTEOLYSIS, (1997), vol. 11, no. suppl. 1, pages 143 - 148, XP001031450 | [L] - KOUTROUBAKIS I E ET AL, "Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease.", AMERICAN JOURNAL OF GASTROENTEROLOGY, (200001), vol. 95, no. 1, pages 190 - 194, XP001030810 [L] 1-4 * Note: Resistance to activated protein C may limit its usefulness. * DOI: http://dx.doi.org/10.1111/j.1572-0241.2000.01683.x |